Immuron (IMRN) Leases (2019)
Immuron's quarterly Leases came in at $77353.0 in Q4 2019.
Immuron has reported Leases for 1 years, with the latest figure at $77353.0 in Q4 2019.
- For the quarter ending Q4 2019, Leases changed N/A year-over-year to $77353.0; the trailing twelve-month figure through Dec 2019 stood at $77353.0 (changed N/A YoY), and the FY2019 full-year result was $77353.0, changed N/A from the prior year.
- Leases for Q4 2019 stood at $77353.0.
- The five-year high for Leases was $77353.0 in Q4 2019, with the low at $77353.0 in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 61,822.50 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 189.30 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 77,353.00 |